Title |
One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy
|
---|---|
Published in |
Frontiers in Cardiovascular Medicine, August 2024
|
DOI | 10.3389/fcvm.2024.1429230 |
Authors |
Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Yaanik B. Desai, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Marco V. Perez, Masataka Kawana, Karim I. Sallam, Chad S. Weldy, Matthew T. Wheeler, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Masataka Kawana, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Cindy Lamendola, Allysonne Smith, Nancy Robles, Colleen Bonnett, Ellen Bacolor, Kimberly Hecker, Isabella Cuenco, Beth Kao, Elise Munsey, Andrea Linder, Kathleen Lacar, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Andrea Linder, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 33% |
Members of the public | 1 | 33% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |